OTCMKTS:GTHP Guided Therapeutics (GTHP) Stock Price, News & Analysis $0.29 0.00 (0.00%) As of 08/7/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsBuy This Stock About Guided Therapeutics Stock (OTCMKTS:GTHP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Guided Therapeutics alerts:Sign Up Key Stats Today's Range$0.29▼$0.2950-Day Range$0.19▼$0.3252-Week Range$0.12▼$0.54VolumeN/AAverage Volume6,287 shsMarket Capitalization$28.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Guided Therapeutics, Inc. is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations. The company secured 510(k) clearance from the U.S. Food and Drug Administration in 2013 and obtained CE marking for distribution within the European Union, enabling it to market its technology across multiple regions. Guided Therapeutics collaborates with academic and research institutions—including the National Cancer Institute—to validate its imaging algorithms through clinical studies conducted in both the United States and Europe. These partnerships have informed ongoing refinements to the LuViva platform and supported expansion of its distribution channels via direct sales and strategic alliances. Founded in 1993 and headquartered in Melbourne, Florida, Guided Therapeutics leverages a multidisciplinary management team with expertise in biomedical engineering, oncology, and regulatory affairs. Building on the core technology behind LuViva, the company is exploring additional applications in gynecologic and dermatologic diagnostics. Its long-term strategy aims to extend its non‐invasive optical imaging capabilities to address a broader range of clinical needs in early disease detection.AI Generated. May Contain Errors. Read More Receive GTHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GTHP Stock News HeadlinesGuided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese DistributorJuly 22, 2026 | finance.yahoo.comGuided Therapeutics Announces New Agreement with Distribution Partner Yuanshuo Medical Instruments CorporationJuly 14, 2026 | uk.finance.yahoo.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 10 at 1:00 AM | Porter & Company (Ad)Guided Therapeutics Files Premarket Approval Application Clinical Report with FDAJune 16, 2026 | businesswire.comGuided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant OfferingMarch 31, 2026 | finance.yahoo.comAnalysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuVivaDecember 17, 2025 | finance.yahoo.comGuided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese DistributorDecember 11, 2025 | finance.yahoo.comGuided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments CorporationNovember 19, 2025 | finance.yahoo.comSee More Headlines GTHP Stock Analysis - Frequently Asked Questions How have GTHP shares performed this year? Guided Therapeutics' stock was trading at $0.54 at the start of the year. Since then, GTHP stock has decreased by 46.3% and is now trading at $0.29. How were Guided Therapeutics' earnings last quarter? Guided Therapeutics Inc. (OTCMKTS:GTHP) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Guided Therapeutics? Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guided Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Investment Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Enbridge (ENB). Company Calendar Last Earnings5/15/2026Today8/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:GTHP CIK924515 Webwww.guidedinc.com Phone(770) 242-8723Fax770-242-8639Employees5Year Founded1992Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.20 million Net MarginsN/A Pretax Margin-426.21% Return on EquityN/A Return on Assets-274.24% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.07 Sales & Book Value Annual Sales$770 thousand Price / Sales36.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-3.22Miscellaneous Outstanding Shares96,540,000Free Float32,021,000Market Cap$28.00 million OptionableNot Optionable Beta0.71 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:GTHP) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...Awesomely | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredEric Fry’s super simple investing mantraFormer Wall Street money manager Eric Fry says buy and hold investing is outdated. Instead, he built his caree...InvestorPlace | SponsoredI found Rolls-Royce below $2. Now THIS.In 2022, Karim Rahemtulla flagged Rolls-Royce when shares traded below $2 - they later climbed above $10. N...Monument Traders Alliance | SponsoredReal reason Trump banning Chinese modelsPresident Trump's administration is drafting a ban on Chinese-made components used inside American AI data cen...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guided Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guided Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
